Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Reproductive System Cancer
National Cancer Institute (NCI)protein_peptidePhase 1/2Active
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Reproductive System Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
pds0101 National Cancer Institute (NCI) | Phase 1/2 | CCC |
Prgn-2009 National Cancer Institute (NCI) | Phase 1/2 | CCC |
Ibuprofen National Cancer Institute (NCI) | Phase 1/2 | CCC |
Diphenhydramine National Cancer Institute (NCI) | Phase 1/2 | CCC |
Epinephrine National Cancer Institute (NCI) | Phase 1/2 | CCC |
Dexasone National Cancer Institute (NCI) | Phase 1/2 | CCC |
Immunocytokine Nhs-Il12 National Cancer Institute (NCI) | Phase 1/2 | CC |
Same molecule, other indications
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →